echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JAMA: Carrelizumab combined with chemotherapy first-line treatment significantly improves the prognosis of patients with advanced esophageal squamous cell carcinoma: Phase 3 clinical study ESCORT-1st

    JAMA: Carrelizumab combined with chemotherapy first-line treatment significantly improves the prognosis of patients with advanced esophageal squamous cell carcinoma: Phase 3 clinical study ESCORT-1st

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Esophageal cancer is one of the common malignant tumors in China.


    Esophageal cancer is one of the common malignant tumors in China.


    The ESCORT-1 st study is a randomized, double-blind, placebo-controlled, phase III clinical study conducted in more than 60 centers across the country.


    The ESCORT-1 st study is a randomized, double-blind, placebo-controlled, phase III clinical study conducted in more than 60 centers across the country.


    The study finally included 596 patients, 298 cases in each of the Carrelizumab combined chemotherapy group and the chemotherapy group




    Similarly, the Carrelizumab combined chemotherapy group significantly improved the patients’ median progression-free survival (PFS) compared with the chemotherapy group, which were 6.




    The 6-month, 12-month, and 18-month survival rates of the combination group and single chemotherapy group were 89.


    The ORR of the two groups were 72.


    Treatment-related serious adverse events occurred in 296 patients (99.



    Adverse events

    In summary, the study showed that Carrelizumab combined with chemotherapy first-line treatment significantly improved the prognosis of patients with advanced esophageal squamous cell carcinoma


    In summary, the study showed that Carrelizumab combined with chemotherapy first-line treatment significantly improved the prognosis of patients with advanced esophageal squamous cell carcinoma


    Original source:

    Luo H, Lu J, Bai Y, et al.
    ESCORT-1st Investigators.
    Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial .
    JAMA.
    2021 Sep 14;326(10):916-925.
    doi: 10.
    1001/jama.
    2021.
    12836.
    PMID: 34519801.

    Luo H, Lu J, Bai Y, et al.
    ESCORT-1st Investigators.
    Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial .
    JAMA.
    2021 Sep 14;326(10):916-925.
    doi: 10.
    1001/jama.
    2021.
    12836.
    PMID: 34519801.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.